Sanofi-Aventis

Human Rights: By complying with international human rights standards and principles, sanofi-aventis has made a formal commitment to incorporate human rights principles in the Group’s operating activities. The Group’s Code of Ethics takes as its references the Universal Declaration of Human Rights, the United Nations Global Compact, the Organization for Economic Cooperation and Development directives and the International Labor Organization principles, as well as national laws and regulations. The Group is also committed to the right to health for all, as defined in the International Covenant on Economic, Social and Cultural Rights. Furthermore, sanofi-aventis has complied with the 10 Principles of the United Nations Global Compact since 2003. Within the scope of this commitment, each year the Group issues a Communication On Progress (COP),to report on the Group’s progress in human rights to the Secretary-General of the United Nations.

 

Defending Innovation: Sanofi-aventis believes that innovation is the most effective answer to unresolved public health problems (unmet medical needs, technically or economically unadapted treatments, etc.). For this reason, the Group supports public policies and initiatives designed to encourage innovation worldwide.

 

Respecting intellectual property rights: Sanofi-aventis considers respect for intellectual property an essential part of stimulating research and ingencouraging the risk-taking it involves. The Group believes it is important for the international agreements of the World Trade Organization (WTO) to be applied and upheld.

 

Compulsory Licences: In a health emergency situation, in compliance with procedures, or in the event of a serious public health crisis, sanofi-aventis’ position is that intellectual property rights must not stand in the way of access to medicines and vaccines. According to WTO (World Trade Organization) agreements, products manufactured under a compulsory license must be used primarily for crisis management in accordance with TRIPS ( Trade-Related Aspects of Intellectual Property Rights) rules. Through its access to medicines policy, the Group also facilitates, as much as possible, access to its products for economically disadvantaged populations, especially for tropical diseases that primarily affect developing countries.

 

Ensuring the quality of medicines and fighting counterfeit drugs: Sanofi-aventis ensures product quality for patients and medical personnel in all countries throughout the world.
The Group actively supports public authorities efforts, wherever they may be, to guarantee the highest standards of drug quality and safety and fight counterfeit drugs. In accordance with this position, it alerts health authorities of the risks involved in parallel trade and pharmaceutical sales over the Internet. Sanofi-aventis’ position on products in transit:
The Group has made a commitment not to assert its intellectual property rights for products in transit when it can be established that the detained products are legal in the country of destination and the country of origin.

 

Clinical trials : Sanofi-aventis supports efforts to improve clinical trial transparency so that patients and / or healthy volunteers will be well informed about the trials in which they participate and their rights will be protected. It publishes information about its own clinical trials via specialized Internet sites. Regardless of the country where the Group carries out clinical trials, it ensures compliance with ethical standards for the protection of those enrolled in the trials.

 

Patients’ rights: Sanofi-aventis considers that meeting patient needs must be the first criterion to assess the validity and relevance of health policies. Patients should be able to benefit from innovations that can improve their health as quickly as possible without obstruction by unjustified administrative barriers.

 

Access to medicine in developing countries: Sanofi-aventis promotes international solidarity efforts making it possible to finance better access to healthcare for populations in need.
The Group has numerous partnerships with national and international public health organizations (WHO, Global Alliance for Vaccines and Immunization, Nelson Mandela Foundation, etc.).

 

Good commercial practices : The Group adheres to good commercial practices adopted by professional associations to which it belongs (IFPMA, EFPIA and the main national codes in the United States, France, United Kingdom, Germany, Japan, etc.). Sanofi-aventis refutes any coerced prescription practices or those that could be considered corruption.

 

Pediatric drugs : Sanofi-aventis routinely studies the opportunity to develop new pediatric medicines, and meets registration agencies’ requirements. The Group also applies this approach to drugs for the treatment of diseases in developing countries: for example, it produces a pediatric version of the drug combination artesunate + amodiaquine (ASAQ), launched recently by the Group for the treatment of malaria, a disease that especially affects children.

 

Price setting : The Group’s preference is to let the market determine the “fair” price of a medicine, for all drugs that are not reimbursed by a public health insurance system.
In countries where price setting is practiced by administrative authorities, the Group would like prices to take into account the need to pursue today’s research efforts for the sake of tomorrow’s health. In Europe, where prices are set by authorities in the different countries but products circulate freely, the Group has stated its preference for pharmaceutical companies’ freedom to set a single “factory exit” price for Europe with variable national compensation (from one country to another) applied to locally consumed products.

 

Parallel trade : Experience has clearly shown that parallel trade brings very little benefit to patients. In addition, increasing the number of commercial intermediaries makes it more difficult, and sometimes impossible, to ensure product traceability. This may create patient risk, especially in connection with counterfeit products introduced into commercial channels.
For all these reasons, sanofi-aventis has always expressed very strong reservations about the parallel trade of medicine.

 

Biodiversity : In accordance with international standards, Sanofi-aventis has established principles aimed at preserving the biodiversity of natural plant and wild animal species for use in research projects to discover new drugs, and ensuring fair distribution and sharing of benefits resulting from the use of this type of resource with the countries where these species are found. These principles also emphasize that the Group preserves biodiversity surrounding its sites, particularly those located in sensitive natural areas


 

Sanofi Membership in Associations

  • Pharmaceutical Research and Manufacturers of America
  • The French Pharmaceutical Companies Association
  • International Federation of Pharmaceutical Manufacturers and Associations
  • European Federation of Pharmaceutical Industries and Associations
  • European Biopharmaceutical Enterprises
  • Association of the European Self-Medication Industry